Co-Authors
This is a "connection" page, showing publications co-authored by CHARLOTTE C SUN and ANAIS MALPICA.
Connection Strength
0.833
-
Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival. Gynecol Oncol. 2022 11; 167(2):139-145.
Score: 0.214
-
Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. J Clin Oncol. 2017 Apr 01; 35(10):1103-1111.
Score: 0.145
-
Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. J Clin Oncol. 2015 Aug 20; 33(24):2675-82.
Score: 0.130
-
The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes. Gynecol Oncol. 2022 06; 165(3):560-567.
Score: 0.052
-
Low-grade serous ovarian cancer: State of the science. Gynecol Oncol. 2020 03; 156(3):715-725.
Score: 0.044
-
The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer. Gynecol Oncol. 2015 Jan; 136(1):25-9.
Score: 0.031
-
KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. J Pathol. 2013 Dec; 231(4):449-56.
Score: 0.029
-
Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2012 Jun; 125(3):661-6.
Score: 0.026
-
Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer. 2012 Jun 15; 118(12):3087-94.
Score: 0.025
-
Low-grade serous primary peritoneal carcinoma. Gynecol Oncol. 2011 Jun 01; 121(3):482-6.
Score: 0.024
-
BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol. 2010 Oct; 177(4):1611-7.
Score: 0.023
-
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol. 2009 Jul; 114(1):48-52.
Score: 0.021
-
Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2008 Mar; 108(3):510-4.
Score: 0.019
-
Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. Gynecol Oncol. 2007 Jun; 105(3):625-9.
Score: 0.018
-
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006 Aug; 108(2):361-8.
Score: 0.017
-
Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer. 2003 Aug 15; 98(4):758-64.
Score: 0.014